mirtazapine has been researched along with Obsessive-Compulsive Disorder in 10 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aim is to assess the efficacy of mirtazapine augmentation for patients with obsessive-compulsive disorder (OCD) who did not respond to sertraline monotherapy." | 9.69 | Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. ( Baniasadipour, H; Mowla, A, 2023) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 7.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| " Our aim is to assess the efficacy of mirtazapine augmentation for patients with obsessive-compulsive disorder (OCD) who did not respond to sertraline monotherapy." | 5.69 | Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. ( Baniasadipour, H; Mowla, A, 2023) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 3.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mowla, A | 1 |
| Baniasadipour, H | 1 |
| Lim, LJH | 1 |
| Fong, LM | 1 |
| Hariram, J | 1 |
| Lee, YW | 1 |
| Tor, PC | 1 |
| Jaffe, RJ | 2 |
| Juneja, NS | 2 |
| Coffey, BJ | 1 |
| Waltereit, R | 1 |
| Eifler, S | 1 |
| Schirmbeck, F | 1 |
| Zink, M | 1 |
| Conrad, R | 1 |
| Wegener, I | 1 |
| Geiser, F | 1 |
| Imbierowicz, K | 1 |
| Liedtke, R | 1 |
| Egashira, N | 1 |
| Shirakawa, A | 1 |
| Abe, M | 1 |
| Niki, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Chen, JL | 1 |
| Spinowitz, N | 1 |
| Karwa, M | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Koran, LM | 2 |
| Gamel, NN | 1 |
| Choung, HW | 1 |
| Smith, EH | 1 |
| Aboujaoude, EN | 1 |
| Quirk, T | 1 |
| Lorberbaum, JP | 1 |
| Elliott, M | 1 |
4 trials available for mirtazapine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
Topics: Humans; Mirtazapine; Obsessive-Compulsive Disorder; Sertraline | 2023 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Topics: Adult; Antidepressive Agents, Tricyclic; Diagnostic and Statistical Manual of Mental Disorders; Doub | 2005 |
Mirtazapine treatment of obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Dose-Response Relationship, Drug; Female; Humans; Male; Mia | 2001 |
6 other studies available for mirtazapine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
COVID-19, a pandemic that affects more than just physical health: Two case reports.
Topics: Adjustment Disorders; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; COVID-19; Fear; Female; Hu | 2020 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety | 2018 |
Visual and auditory hallucinations associated with citalopram treatment.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D | 2013 |
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.
Topics: Adult; Anorexia Nervosa; Benzodiazepines; Calcinosis; Combined Modality Therapy; Dominance, Cerebral | 2008 |
N-acetyl-L-cysteine inhibits marble-burying behavior in mice.
Topics: Acetylcysteine; alpha-Tocopherol; Animals; Antipsychotic Agents; Anxiety Disorders; Behavior, Animal | 2012 |
Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report.
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Diabetic Ketoacidosis; | 2003 |